PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
Status:
Completed
Trial end date:
2021-06-08
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that Tadalafil treatment, by lowering Myeloid Derived
Suppressor Cells (MDSCs) and regulatory T cells (Tregs), can prime an antitumor immune
response and promote a permissive environment that should increase the efficacy of anti-tumor
vaccine in a setting of minimal residual disease.